Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 12:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Doxazosin Clear all
Completed Phase 2 Interventional Results available

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

NCT02500602
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Alcohol Use Disorders
Interventions
doxazosin, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 4 Interventional Results available

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Lisinopril, Lisinopril and Hydrochlorothiazide, Nifedipine XL, Metoprolol tartrate, Atenolol, Valsartan, Doxazosin, Clonidine, Hydralazine, Metoprolol succinate, Amlodipine
Drug
Lead sponsor
Creighton University
Other
Eligibility
25 Years to 80 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 1, 2026, 12:57 PM EDT
Not listed Phase 2 Interventional

A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

NCT03339258
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin Mesylate, Extended Release, Placebo
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

DOXAZOSIN FOR PTSD

NCT02308202
View directory record Official record
Conditions
PTSD
Interventions
doxazosin, Perindopril, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

Complementary Combination Therapy for Cocaine Dependence

NCT02538744
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Modafinil, cocaine, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 1, 2026, 12:57 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Early Phase 1 Interventional

Doxazosin an a1 Antagonist for Alcohol Dependence

NCT01437046
View directory record Official record
Conditions
Alcohol Dependence, Anxiety
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 3 Interventional Results available

Preoperative Alpha Blockade for Pheochromocytoma

NCT03176693
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Phenoxybenzamine, Doxazosin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2023 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 4 Interventional Results available

Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart

NCT01798992
View directory record Official record
Conditions
Idiopathic Dilated Cardiomyopathy
Interventions
Carvedilol, Metoprolol succinate, Metoprolol succinate + doxazosin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

NCT02989493
View directory record Official record
Conditions
Alcoholism
Interventions
Doxazosin, Placebo
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1 Interventional

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

NCT01062945
View directory record Official record
Conditions
Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions
Placebo, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Results available

Pharmacogenetics of Doxazosin for Cocaine Dependence

NCT01145183
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 1, 2026, 12:57 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Alfuzosin for Medical Expulsion Therapy of Ureteral Stones

NCT00713739
View directory record Official record
Conditions
Kidney Stones
Interventions
Alfuzosin, nifedipine, doxazosin, prazosin
Drug
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin

NCT00645034
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
placebo, sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
35 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
2
States / cities
Laguna Woods, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Sugar Pill, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 3 Interventional

Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes

NCT00004266
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Lisinopril, Nifedipine, Simvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse

NCT01953432
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Doxazosin for Psychostimulant Dependence

NCT01371851
View directory record Official record
Conditions
Methamphetamine or Cocaine Dependence
Interventions
Doxazosin extended release
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 1, 2026, 12:57 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

NCT03415581
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Intranasal Oxycodone, Cue Session
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Hemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin

NCT01100021
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Tamsulosin and avanafil, Doxazosin and avanafil
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Sep 1, 2026, 12:57 PM EDT
Recruiting Phase 2 Interventional

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

NCT04135846
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Doxazosin, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 1, 2026, 12:57 PM EDT
Completed Phase 4 Interventional

A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD

NCT01959022
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Doxazosin XL
Drug
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Sep 1, 2026, 12:57 PM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 1, 2026, 12:57 PM EDT